Abstract
The outcome of L-thyroxine (L-T4) replacement therapy in children with congenital hypothyroidism (CH) remains to be completely evaluated. In this paper the overall pattern of response to L-T4 replacement therapy was studied in a group of 19 children with CH diagnosed by neonatal screening (10 with hypoplastic/aplastic thyroid disease, group H/A; 9 with gland ectopy, group E) who were followed-up for 60 ± 27 months (mean ± SD). With 1 exception serum T4 at diagnosis was > 2 µg/dl in children of group E and < 2 µg/dl in those of group H/A. The initial dose of L-T4 (8–10 µg/kg BW/day) was modified in relation to age and weight in order to maintain serum TSH ≼ 5 µU/ml and FT3 in the normal range. A general inverse correlation between serum TSH and FT4 or FT3 concentrations was found, and the mean levels of serum FT4 and FT3 were significantly higher according to the following order of TSH results: low TSH (0–0.5 µU/ml) > normal (>0.5–5 µU/ml) > elevated TSH (>5 µU/ml). TSH levels < 5 µU/ml were associated with FT4 values in the upper half of the normal range (54% of observations) or even higher (46%). Elevation of serum FT4 alone with FT3 values in the normal range did not result in clinical thyrotoxicosis, alteration of growth or premature craniosynostosis. Mean L-T4 doses (µg/kg BW/day) administered to CH children were: 7.0 ± 1.6 between 1 and 6 months; 5.2 ± 0.9 between 6 and 12 months; 4.0 ± 0.6 between 1 e 5 yr; 3.4 ± 0.6 over 6 yr. In general, the mean L-T4 closes given to children showing low, normal or elevated TSH were widely overlaped. Growth in weight and height was normal, no significant difference being observed in children of group H/A vs. those of group E. Mental development was within the normal range, but at age 12 months children in group H/A had significantly lower DQ scores than those in group E, and at age 3 yr both groups of CH children had significantly lower IQ scores than unaffected controls. In conclusion: i) in children with CH serum TSH can be suppressed to normal or even subnormal concentrations provided that enough L-T4 is given to maintain FT4 in the upper half of the normal range or slightly higher; ii) sporadic elevations of TSH during treatment could be attributed to: failure to reassess the dose of L-T4 following the infant’s rapid gain in weight, lack of compliance, malabsorption of the drug, misunderstanding of prescription; iii) neuropsychological development was within the normal range of tests; however, the absence of functioning thyroid tissue, as shown by low T4 at diagnosis and by negative radioisotope imaging, was a risk factor for lower mental scores.
Similar content being viewed by others
References
Glorieux J., Desjardins M., Letarte J., Morisette J., Dussault J. H. Useful parameters to predict the eventual mental outcome of hypothyroid children. Pediatr. Res. 24: 6, 1988.
New England Congenital Hypothyroidism Collaborative Neonatal hypothyroidism screening: status of patients at 6 years of age. J. Pediatr. 107: 915, 1985.
Rovet J., Erlich R., Sorbara D. Intellectual outcome in children with fetal hypothyroidism. J. Pediatr. 110: 700, 1987.
Illig R., Largo R.H., Weber M., Augsburger T.H., Lipp A., Wissler D., Perrenoud A.E., Torresani T. Sixty children with congenital hypothyroidism detected by neonatal thyroid screening: mental development at 1, 4 and 7 years: a longitudinal study. Acta Endocrinol. (Copenh.) Suppl. 279: 346, 1986.
Mitchell M.L., Hermos R.J., Frederick D.L., Klein R.Z. Problems in the management of patients with infantile hypothyroidism. In: Delange F., Fisher D.A., Glinoer D. (Eds.), Research in congenital hypothyroidism. Plenum Press, New York, 1989, p. 237.
Sato T., Suzuki Y., Taketani T., Ishiguro K., Nakajima H. Age related change in pituitary threshold for TSH release during thyroxine replacement therapy for cretinism. J. Clin. Endocrinol. Metab. 44: 553, 1977.
Abusrewil S.S.A., Tyfield L., Savage D.C.L. Serum thyroxine and thyroid stimulating hormone concentrations after treatment of congenital hypothyroidism. Arch. Dis. Child. 63: 1368, 1988.
Larsen P.R. Maternal thyroxine and congenital hypothyroidism. N. Engl. J. Med. 321: 44, 1989.
Romelli P.B., Pennisi F., Vancheri L. Measurements of free thyroid hormones in serum by column adsorption chromatography and radioimmunoassay. J. Endocrinol. Invest. 2: 25, 1979.
Bartalena L., Martino E., Pacchiarotti A., Grasso L., Aghini-Lombardi A., Buratti L., Bambini G., Breccia M., Pinchera A. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J. Clin. Endocrinol. Metab. 64: 849, 1987.
Focarile F., Rondanini G.F., Bollati A., Bartolucci A., Chiumello G. Free thyroid hormones in evaluating persistently elevated thyrotropin levels in children with congenital hypothyroidism on replacement therapy. J. Clin. Endocrinol. Metab. 59: 1211, 1984.
Galen R.S., Gambino S.L. Beyond normality: the predictive value and efficiency of medical diagnoses. John Wiley & Sons, New York, 1980.
Ingbar J.C., Borges M., Ifiah S., Kleimmann R.E., Braverman L.E., Ingbar S.H. Elevated serum thyroxine concentrations in patients receiving “replacement” dose of levothyroxine. J. Endocrinol. Invest. 5: 77, 1982.
Rendell M., Salmon D. “Chemical hyperthyroidism”: The significance of elevated serum thyroxine levels in L-thyroxine treated individuals. Clin. Endocrinol. (Oxf.) 22: 693, 1985.
Jennings P.E., O’Malley B.P., Griffin K.E., Northover B., Rosenthal F.D. Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: A case of “tissue thyrotoxicosis”. Br. Med. J. 369: 1645, 1984.
Gow S.M., Caldwell G., Toft A.D., Seth J., Hussey A.J., Sweeting V.M., Beckett G.J. Relationship between pituitary and other organ responsiveness in hypothyroid patients receiving thyroxine replacement. J. Clin. Endocrinol. Metab. 64: 364, 1987.
Klein R.Z. History of congenital hypothyroidism. In: Burrow G.N., Dussault J.H. (Eds.), Neonatal thyroid screening. Raven Press, New York, 1980, p. 51.
Vulsma T., Gons M.H., DeVijIder J.J.M. Maternal fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N. Engl. J. Med. 321: 13, 1989.
Illig R., Largo R.H., Qin Q., Torresani T., Rochiccioli P., Larsson A. Mental development in congenital hypothyroidism after neonatal screening. Arch. Dis. Child. 62: 1050, 1987.
Fisher D.A., Foley B.L. Early treatment of congenital hypothyroidism. Pediatrics 83: 785, 1989.
Daneman D., Howard N.J. Neonatal thyrotoxicosis, intellectual impairment and craniosynostosis in later years. J. Pediatr. 97: 257, 1980.
Penfold J.L., Simpson D.A. Premature craniosynostosis, a complication of thyroid replacement therapy. J. Pediatr. 66: 360, 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiovato, L., Giusti, L., Tonacchera, M. et al. Evaluation of L-thyroxine replacement therapy in children with congenital hypothyroidism. J Endocrinol Invest 14, 957–964 (1991). https://doi.org/10.1007/BF03347122
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347122